Our Portfolio

Deerfield portfolio companies strive to advance healthcare in meaningful and innovative ways.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters
Industry
Clear
Purpose of Financing
Clear
Stage
Clear
Structure of Financing
Clear
Status of Investment
Clear
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tag
:
Tag
Showing 0 of 100
R3 Vascular
R3 Vascular
Medical Technologies
Apr 2024
Venture
Mid Stage
Equity
Current
Pleno
Pleno
Medical Technologies
Aug 2022
Venture
Early Stage
Equity
Current
Presidio Medical
Presidio Medical
Medical Technologies
May 2023
Venture
Mid Stage
Equity
Current
Petfolk
Petfolk
Healthcare Services
Oct 2024
Venture
Mid Stage
Equity
Current
Perceive Pharma
Perceive Pharma
Therapeutics
Dec 2024
Venture
Mid Stage
Equity
Current
Perceive Biotherapeutics
Perceive Biotherapeutics
Therapeutics
Aug 2018
Venture
Early Stage
Equity
Current
Pairwise
Pairwise
Therapeutics
Jun 2017
Venture
Seed/Startup
Debt and Equity
Current
Nuo Therapeutics
Nuo Therapeutics
Medical Technologies
Mar 2014
Special Situations
Mature
Debt and Equity
Current
Omnigen
Omnigen
Healthcare Services
Jun 2021
Special Situations
Early Stage
Debt and Equity
Current
Neomorph
Neomorph
Therapeutics
Mar 2020
Venture
Seed/Startup
Debt and Equity
Current
Nema Health
Nema Health
Healthcare Services
Oct 2024
Venture
Early Stage
Equity
Current
Melinta Therapeutics
Melinta Therapeutics
Therapeutics
Nov 2017
Growth
Growth
Debt
Current
myLaurel
myLaurel
Healthcare Services
Nov 2019
Growth
Mid Stage
Equity
Current
Meditrina
Meditrina
Medical Technologies
Apr 2020
Growth
Mid Stage
Equity
Current
Civetta Therapeutics
Civetta Therapeutics
Therapeutics
Feb 2019
Venture
Seed/Startup
Debt and Equity
Current
DISCLAIMER

The portfolio companies shown represents a significant portion of the current portfolio of Deerfield funds utilizing the Private Design Strategy or Healthcare Innovations Strategy.  Exclusions include historical investments, research projects and related entities, companies in stealth mode, companies without material operations, companies in which Deerfield funds hold residual interests, investments in other funds, and investment portfolios of other Deerfield strategies. The specific portfolio companies identified are not representative of all of the portfolio companies purchased, sold, or recommended for Deerfield funds, and it should not be assumed that any investment in an identified portfolio company was or will be profitable. Actual holdings will vary for each Deerfield fund and there is no guarantee that a particular Deerfield fund will hold any or all of the portfolio companies listed.